BenevolentAI
strategic validation successful collaboration with year target collaboration is delivering multiple novel targets for complex diseases with high unmet need separate data environment established to integrate data into a bespoke knowledge graph and teams working in close collaboration to explore identify and validate targets therapeutic areas initial deal expansion key milestones deal structure of license fee milestone payments and downstream royalties to date three novel targets have been validated selected for portfolio collaboration enables to enrich its platform via the data generated as part of the collaboration but also further validate the use of our platform may | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
24 of 74
Similar slides by BenevolentAI
See diffirences between slides (animation)
Results
March 2023
strategic validation successful collaboration with year target collaboration is delivering multiple novel targets for complex diseases with high unmet need separate data environment established to integrate data into a bespoke knowledge graph and teams working in close collaboration to explore identify and validate targets deal structure of license fee milestone payments and downstream royalties data generated via the collaboration enriches the benevolent platform five novel targets selected for portfolio to date initial deal focussed on chronic kidney disease idiopathic pulmonary fibrosis year collaboration expansion to include heart failure systemic lupus | BenevolentAI
Investor Conference
January 2023
strategic validation successful collaboration with year target collaboration is delivering multiple novel targets for complex diseases with high unmet need separate data environment established to integrate data into a bespoke knowledge graph and teams working in close collaboration to explore identify and validate targets deal structure of license fee milestone payments and downstream royalties data generated via the collaboration enriches the benevolent platform five novel targets selected for portfolio to date initial deal focussed on chronic kidney disease idiopathic pulmonary fibrosis year collaboration expansion to include heart failure systemic lupus | BenevolentAI
Investor Conference
November 2022
strategic validation successful collaboration with year target collaboration is delivering multiple novel targets for complex diseases with high unmet need separate data environment established to integrate data into a bespoke knowledge graph therapeutic areas initial deal expansion and teams working in close collaboration to explore identify and validate targets key milestones deal structure of license fee milestone payments and downstream royalties to date novel targets have been validated selected for portfolio collaboration enables to enrich its platform via the data generated as part of the collaboration but also further validate the use of our platform | BenevolentAI
Investor Presentation
October 2022
strategic validation successful collaboration with year target collaboration is delivering multiple novel targets for complex diseases with high unmet need separate data environment established to integrate data into a bespoke knowledge graph therapeutic areas initial deal expansion and teams working in close collaboration to explore identify and validate targets key milestones deal structure of license fee milestone payments and downstream royalties to date novel targets have been validated selected for portfolio collaboration enables to enrich its platform via the data generated as part of the collaboration but also further validate the use of our platform | BenevolentAI
Related slides by other companies
Sonos
Results
November 2021
expansion of our offerings | Sonos
Other recent decks by BenevolentAI
See all presentations (11 decks)
Investor Presentation
September 2024
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights